1-[5-methyl-1-(2-pyridyl)pyrazol-4-yl]ethanone | 5078-64-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-[5-methyl-1-(2-pyridyl)pyrazol-4-yl]ethanone
• 英文别名: 1-(5-methyl-1-pyridin-2-yl-1H-pyrazol-4-yl)ethanone；1-(2'-Pyridyl)-4-acetyl-5-methylpyrazol；4-acetyl-1-(pyridin-2-yl)-5-methylpyrazole；4-acetyl-1-(2-pyridyl)-5-methylpyrazole；1-[5-methyl-1-(pyridin-2-yl)-1H-pyrazol-4-yl]ethan-1-one；1-(5-methyl-1-pyridin-2-ylpyrazol-4-yl)ethanone
• CAS: 5078-64-8
• 化学式: C₁₁H₁₁N₃O
• mdl: MFCD00112454
• 分子量: 201.228
• InChiKey: YIRYAUXPAJGLSK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  47.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-[5-methyl-1-(2-pyridyl)pyrazol-4-yl]ethanone 在 盐酸 、 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 50.0h， 生成
  参考文献：
  名称：

  Synthesis and Antitumor Activity of Novel Pyrimidinyl Pyrazole Derivatives. III. Synthesis and Antitumor Activity of 3-Phenylpiperazinyl-1-trans-propenes

  摘要：

  一系列新型的3-[4-苯基-1-哌嗪基]-1-[5-甲基-1-(2-嘧啶基)-4-吡唑基]-1-反式丙烯及其相关化合物被合成，并通过其对几种肿瘤细胞系的体外细胞毒性活性和对某些肿瘤模型的体内抗肿瘤活性进行了评估，这些化合物既可以通过腹腔注射给药，也可以口服给药。具有3-氯吡啶-2-基团（9g）和3-氟-5-取代苯基哌嗪基团（29b、c和e）的化合物在体外测试中显示出显著的细胞毒性。其中，3-氰基-5-氟苯基衍生物（29b）表现出对包括人癌在内的几种肿瘤细胞的强效抗肿瘤活性，且在老鼠中没有引起不良反应。

  DOI：

  10.1248/cpb.53.153
• 作为产物：
  描述：

  2-肼吡啶 、 3-乙氧亚甲基-2,4-戊二酮 以 乙醇 为溶剂， 反应 1.0h， 以74%的产率得到1-[5-methyl-1-(2-pyridyl)pyrazol-4-yl]ethanone
  参考文献：
  名称：

  Synthesis and Antitumor Activity of Novel Pyrimidinyl Pyrazole Derivatives. III. Synthesis and Antitumor Activity of 3-Phenylpiperazinyl-1-trans-propenes

  摘要：

  一系列新型的3-[4-苯基-1-哌嗪基]-1-[5-甲基-1-(2-嘧啶基)-4-吡唑基]-1-反式丙烯及其相关化合物被合成，并通过其对几种肿瘤细胞系的体外细胞毒性活性和对某些肿瘤模型的体内抗肿瘤活性进行了评估，这些化合物既可以通过腹腔注射给药，也可以口服给药。具有3-氯吡啶-2-基团（9g）和3-氟-5-取代苯基哌嗪基团（29b、c和e）的化合物在体外测试中显示出显著的细胞毒性。其中，3-氰基-5-氟苯基衍生物（29b）表现出对包括人癌在内的几种肿瘤细胞的强效抗肿瘤活性，且在老鼠中没有引起不良反应。

  DOI：

  10.1248/cpb.53.153

文献信息

• Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
  申请人：Altenbach J. Robert

  公开号：US20050272728A1

  公开（公告）日：2005-12-08

  Compounds of formula (I) wherein R 1 or R 2 is an aromatic or non-aromatic ring directly joined or joined by a linker, as represented by L 2 and L 3 , to a heteroaromatic core, and X, X′, Y, Y′, Z, Z′, R 1 , R 2 , R 3 , R 3a , R 3b , R 4 , R 5 , L, L 2 , and L 3 are as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

  式（I）的化合物，其中R1或R2是直接连接或通过连接物连接的芳香或非芳香环，如由L2和L3表示，连接到杂环核心，以及X、X'、Y、Y'、Z、Z'、R1、R2、R3、R3a、R3b、R4、R5、L、L2和L3如本文所定义，可用于治疗由组胺-3受体配体预防或改善的病症或疾病。还公开了包含组胺-3受体配体的药物组合物，使用这类化合物和组合物的方法，以及制备符合式（I）范围内化合物的方法。
• Synthesis, Potency, and In Vivo Profiles of Quinoline Containing Histamine H₃ Receptor Inverse Agonists
  作者：Robert J. Altenbach、Huaqing Liu、Patricia N. Banfor、Kaitlin E. Browman、Gerard B. Fox、Ryan M. Fryer、Victoria A. Komater、Kathleen M. Krueger、Kennan Marsh、Thomas R. Miller、Jia Bao Pan、Liping Pan、Minghua Sun、Christine Thiffault、Jill Wetter、Chen Zhao、Deliang Zhou、Timothy A. Esbenshade、Arthur A. Hancock、Marlon D. Cowart

  DOI：10.1021/jm0705051

  日期：2007.11.1

  A new structural series of histamine H3 receptor antagonist was developed. The new compounds are based on a quinoline core, appended with a required basic aminoethyl moiety, and with potency- and property-modulating heterocyclic substituents. The analogs have nanomolar and subnanomolar potency for the rat and human H3R in various in vitro assays, including radioligand competition binding as well as

  开发了组胺H3受体拮抗剂的新结构系列。新化合物基于喹啉核心，并附加了所需的碱性氨乙基部分以及具有调节效能和特性的杂环取代基。类似物在各种体外测定中对大鼠和人H3R具有纳摩尔和亚纳摩尔效价，包括放射性配体竞争结合以及H3受体介导的钙动员和GTPgammaS结合的功能测试。这些化合物具有良好的类药物特性，例如良好的PK，CNS渗透性和跨物种的适度蛋白质结合。发现几种化合物在认知和注意力的动物行为模型中是有效的。
• [EN] BICYCLIC-SUBSTITUTED AMINES HAVING CYCLIC-SUBSTITUTED MONOCYCLIC SUBSTITUENTS<br/>[FR] AMINES À SUBSTITUTION BICYCLIQUE AYANT DES SUBSTITUANTS MONOCYCLIQUES À SUBSTITUTION CYCLIQUE
  申请人：ABBOTT LAB

  公开号：WO2005113551A1

  公开（公告）日：2005-12-01

  Compounds of formula (I) wherein R1 or R2 is an aromatic or non-aromatic ring directly joined or joined by a linker, as represented by L2 and L3, to a heteroaromatic core, and X, X', Y, Y', Z, Z', R1, R2, R3, R3a, R3b, R4, R5, L, L2, and L3 are as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

  公式（I）的化合物中，其中R1或R2是芳香或非芳香环，直接连接或通过连接剂L2和L3连接到杂环芳香核心，而X，X'，Y，Y'，Z，Z'，R1，R2，R3，R3a，R3b，R4，R5，L，L2和L3如本文所定义，可用于治疗由组胺-3受体配体预防或改善的疾病或症状。还公开了包含组胺-3受体配体的制药组合物，使用这些化合物和组合物的方法，以及制备公式（I）范围内的化合物的方法。
• Pyrazole derivatives
  申请人：Daiichi Pharmaceutical Co., Ltd.

  公开号：US06552018B1

  公开（公告）日：2003-04-22

  The present invention relates to cis- and trans-forms of pyrazole derivatives, salts thereof, or agents containing the same, and represented by the general formula (I): wherein G represents a nitrogen containing saturated heterocyclic structure represented by the following formula: These compounds exhibit anti-tumor activity on 5-FU-resistant tumors and effects on P glycoprotein expressing, multiple-drug resistant tumors. An example of a pyrazole derivative which demonstrates 50% inhibition of tumor cell growth is 3-[4-(3-chloro-5-fluorophenyl)-1piperazinyl]-1-[1-(3-chloro-2-pyridyl)-5-methyl-4-pyrazolyl)-1-trans-propene hydrochloride. Synthesis of the compounds represented by formula (I) can be prepared by any one of various routes such as a Mannich reaction, a Wittig reaction, reductive amination or substitution by allylation.

  本发明涉及吡唑衍生物的顺式和反式形式，其盐或含有该物的药剂，由下式所表示的G代表氮含有饱和杂环结构：这些化合物在5-FU耐药肿瘤上表现出抗肿瘤活性，并对表达P糖蛋白、多药耐药肿瘤有影响。一种表现出50％肿瘤细胞生长抑制的吡唑衍生物的例子是3-［4-（3-氯-5-氟苯基）-1哌嗪基］-1-［1-（3-氯-2-吡啶基）-5-甲基-4-吡唑基］-1-顺-丙烯酸盐酸盐。式（I）所表示的化合物的合成可以通过曼尼希反应、威特格反应、还原胺或烯丙基取代等各种途径之一来制备。
• PYRAZOLE DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1022270A1

  公开（公告）日：2000-07-26

  A compound represented by formula (I) or a salt thereof; wherein R1 and R2, which may be the same or different, each represent a hydrogen atom, a halogen atom, a hydroxy group, an alkoxy group, an amino group, an alkylamino group, an aryl group or an alkyl group; R3 and R4, which may be the same, or different, each represent a hydrogen atom, a halogen atom, an alkoxy group, an amino group, an alkylamino group, an aryl group or an alkyl group; R5 represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group or an arylalkyl group; Q represents an amidino group, a cycloalkyl group, a phenyl group or amonocyclic heterocyclic group except a pyrimidinyl group bonded to the N atom at its 2-position; G represents a nitrogen-containing saturated heterocyclic structure represented by formula: wherein X1 represents a nitrogen atom or CH, in which the ring may have a keto group and may have one or more substituents; Z represents a phenyl or heterocyclic group which may have one or more substituents, in which two substituents on the phenyl or heterocyclic group may be connected to each other to form a ring to provide a condensed bicyclic structure as a whole; the substituent on Z and the substituent on G may be connected to each other to form a condensed tricyclic or tetracyclic structure as a whole, and an antitumor agent containing the compound or a salt thereof as an active ingredient.

  式 (I) 所代表的化合物或其盐； 其中 R1 和 R2 可以相同或不同，各自代表氢原子、卤素原子、羟基、烷氧基、氨基、烷基氨基、芳基或烷基； R3 和 R4 可以相同或不同，各自代表氢原子、卤素原子、烷氧基、氨基、烷基氨基、芳基或烷基；R5 代表氢原子、烷基、烯基、炔基、芳基或芳烷基； Q 代表脒基、环烷基、苯基或胺环杂环基团，但在 2 位与 N 原子键合的嘧啶基除外； G 代表由式表示的含氮饱和杂环结构： 其中 X1 代表氮原子或 CH、 其中环可具有酮基，并可具有一个或多个取代基； Z代表苯基或杂环基团，可具有一个或多个取代基，其中苯基或杂环基团上的两个取代基可相互连接形成一个环，以提供一个整体的缩合双环结构；Z上的取代基和G上的取代基可以相互连接，形成一个缩合的三环或四环结构整体，以及含有该化合物或其盐作为活性成分的抗肿瘤剂。